Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2001 May;70(5):644–648. doi: 10.1136/jnnp.70.5.644

Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system

S Glasker 1, B Bender 1, T Apel 1, V van Velthoven 1, L Mulligan 1, J Zentner 1, H Neumann 1
PMCID: PMC1737358  PMID: 11309459

Abstract

OBJECTIVES—Cerebellar haemangioblastoma occurs sporadically or as a component tumour of autosomal dominant von Hippel-Lindau disease. Biallelic inactivation of the VHL tumour suppressor gene, which is located on chromosome 3p, has been shown to be involved in the pathogenesis of both tumour entities. Mechanisms of VHL inactivation are intragenic mutations, mitotic recombination events, and hypermethylation of the promoter region. The systematic and complete examination of these genetic and epigenetic phenomena in large series of von Hippel-Lindau disease related and sporadic hemangioblastomas has, thus far, not been performed.
METHODS—In the largest series to date, 29 von Hippel-Lindau disease associated and 13 sporadic haemangioblastomas were investigated for all suggested inactivating mechanisms of the VHL gene using single strand conformational polymorphism (SSCP), loss of heterozygosity (LOH), and methylation analyses. Additionally, corresponding blood samples of all patients were screened for VHL germline mutations by SSCP and Southern blotting.
RESULTS—Germline mutations were identified in 94% of patients with von Hippel-Lindau disease and their tumours and 62% of these hemangioblastomas showed LOH of chromosome 3p. Of the 13 sporadic tumours, 23% showed a single somatic mutation of the VHL gene that was not present in the germline. 3p LOH was identified in 50% of informative sporadic tumours. No von Hippel-Lindau disease related or sporadic tumour demonstrated VHL promoter hypermethylation.
CONCLUSIONS—For most von Hippel-Lindau disease related haemangioblastomas, the inactivation or loss of both alleles of the VHL gene, as predicted by the Knudson two hit theory, is required. However, in a subset of tumours including most sporadic haemangioblastomas, the genetic pathways involved in tumorigenesis have yet to be defined and may represent alterations of a different pathway or pathways.



Full Text

The Full Text of this article is available as a PDF (135.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baylin S. B., Herman J. G., Graff J. R., Vertino P. M., Issa J. P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res. 1998;72:141–196. [PubMed] [Google Scholar]
  2. Budowle B., Chakraborty R., Giusti A. M., Eisenberg A. J., Allen R. C. Analysis of the VNTR locus D1S80 by the PCR followed by high-resolution PAGE. Am J Hum Genet. 1991 Jan;48(1):137–144. [PMC free article] [PubMed] [Google Scholar]
  3. Clifford S. C., Prowse A. H., Affara N. A., Buys C. H., Maher E. R. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis. Genes Chromosomes Cancer. 1998 Jul;22(3):200–209. doi: 10.1002/(sici)1098-2264(199807)22:3<200::aid-gcc5>3.0.co;2-#. [DOI] [PubMed] [Google Scholar]
  4. Crossey P. A., Foster K., Richards F. M., Phipps M. E., Latif F., Tory K., Jones M. H., Bentley E., Kumar R., Lerman M. I. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum Genet. 1994 Jan;93(1):53–58. doi: 10.1007/BF00218913. [DOI] [PubMed] [Google Scholar]
  5. Glavac D., Neumann H. P., Wittke C., Jaenig H., Masek O., Streicher T., Pausch F., Engelhardt D., Plate K. H., Höfler H. Mutations in the VHL tumor suppressor gene and associated lesions in families with von Hippel-Lindau disease from central Europe. Hum Genet. 1996 Sep;98(3):271–280. doi: 10.1007/s004390050206. [DOI] [PubMed] [Google Scholar]
  6. Gläsker S., Bender B. U., Apel T. W., Natt E., van Velthoven V., Scheremet R., Zentner J., Neumann H. P. The impact of molecular genetic analysis of the VHL gene in patients with haemangioblastomas of the central nervous system. J Neurol Neurosurg Psychiatry. 1999 Dec;67(6):758–762. doi: 10.1136/jnnp.67.6.758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Gnarra J. R., Tory K., Weng Y., Schmidt L., Wei M. H., Li H., Latif F., Liu S., Chen F., Duh F. M. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet. 1994 May;7(1):85–90. doi: 10.1038/ng0594-85. [DOI] [PubMed] [Google Scholar]
  8. Ivanov S. V., Kuzmin I., Wei M. H., Pack S., Geil L., Johnson B. E., Stanbridge E. J., Lerman M. I. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12596–12601. doi: 10.1073/pnas.95.21.12596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Jones M. H., Yamakawa K., Nakamura Y. Isolation and characterization of 19 dinucleotide repeat polymorphisms on chromosome 3p. Hum Mol Genet. 1992 May;1(2):131–133. doi: 10.1093/hmg/1.2.131. [DOI] [PubMed] [Google Scholar]
  10. Jones P. A., Laird P. W. Cancer epigenetics comes of age. Nat Genet. 1999 Feb;21(2):163–167. doi: 10.1038/5947. [DOI] [PubMed] [Google Scholar]
  11. Kanno H., Kondo K., Ito S., Yamamoto I., Fujii S., Torigoe S., Sakai N., Hosaka M., Shuin T., Yao M. Somatic mutations of the von Hippel-Lindau tumor suppressor gene in sporadic central nervous system hemangioblastomas. Cancer Res. 1994 Sep 15;54(18):4845–4847. [PubMed] [Google Scholar]
  12. Latif F., Tory K., Gnarra J., Yao M., Duh F. M., Orcutt M. L., Stackhouse T., Kuzmin I., Modi W., Geil L. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993 May 28;260(5112):1317–1320. doi: 10.1126/science.8493574. [DOI] [PubMed] [Google Scholar]
  13. Lee J. Y., Dong S. M., Park W. S., Yoo N. J., Kim C. S., Jang J. J., Chi J. G., Zbar B., Lubensky I. A., Linehan W. M. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res. 1998 Feb 1;58(3):504–508. [PubMed] [Google Scholar]
  14. Maxwell P. H., Wiesener M. S., Chang G. W., Clifford S. C., Vaux E. C., Cockman M. E., Wykoff C. C., Pugh C. W., Maher E. R., Ratcliffe P. J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999 May 20;399(6733):271–275. doi: 10.1038/20459. [DOI] [PubMed] [Google Scholar]
  15. Neumann H. P. Basic criteria for clinical diagnosis and genetic counselling in von Hippel-Lindau syndrome. Vasa. 1987;16(3):220–226. [PubMed] [Google Scholar]
  16. Neumann H. P., Bender B. U. Genotype-phenotype correlations in von Hippel-Lindau disease. J Intern Med. 1998 Jun;243(6):541–545. doi: 10.1046/j.1365-2796.1998.00336.x. [DOI] [PubMed] [Google Scholar]
  17. Neumann H. P., Lips C. J., Hsia Y. E., Zbar B. Von Hippel-Lindau syndrome. Brain Pathol. 1995 Apr;5(2):181–193. doi: 10.1111/j.1750-3639.1995.tb00592.x. [DOI] [PubMed] [Google Scholar]
  18. Oberstrass J., Reifenberger G., Reifenberger J., Wechsler W., Collins V. P. Mutation of the Von Hippel-Lindau tumour suppressor gene in capillary haemangioblastomas of the central nervous system. J Pathol. 1996 Jun;179(2):151–156. doi: 10.1002/(sici)1096-9896(199606)179:2<151::aid-path556>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  19. Ohh M., Yauch R. L., Lonergan K. M., Whaley J. M., Stemmer-Rachamimov A. O., Louis D. N., Gavin B. J., Kley N., Kaelin W. G., Jr, Iliopoulos O. The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix. Mol Cell. 1998 Jun;1(7):959–968. doi: 10.1016/s1097-2765(00)80096-9. [DOI] [PubMed] [Google Scholar]
  20. Pause A., Lee S., Lonergan K. M., Klausner R. D. The von Hippel-Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal. Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):993–998. doi: 10.1073/pnas.95.3.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Payne S. J., Richards F. M., Maher E. R. A PCR generated AccI RFLP in the 3' untranslated region of the von Hippel-Lindau disease (VHL) tumour suppressor gene. Hum Mol Genet. 1994 Feb;3(2):390–390. doi: 10.1093/hmg/3.2.390. [DOI] [PubMed] [Google Scholar]
  22. Prowse A. H., Webster A. R., Richards F. M., Richard S., Olschwang S., Resche F., Affara N. A., Maher E. R. Somatic inactivation of the VHL gene in Von Hippel-Lindau disease tumors. Am J Hum Genet. 1997 Apr;60(4):765–771. [PMC free article] [PubMed] [Google Scholar]
  23. Sekido Y., Bader S., Latif F., Gnarra J. R., Gazdar A. F., Linehan W. M., Zbar B., Lerman M. I., Minna J. D. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines. Oncogene. 1994 Jun;9(6):1599–1604. [PubMed] [Google Scholar]
  24. Stolle C., Glenn G., Zbar B., Humphrey J. S., Choyke P., Walther M., Pack S., Hurley K., Andrey C., Klausner R. Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat. 1998;12(6):417–423. doi: 10.1002/(SICI)1098-1004(1998)12:6<417::AID-HUMU8>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
  25. Tse J. Y., Wong J. H., Lo K. W., Poon W. S., Huang D. P., Ng H. K. Molecular genetic analysis of the von Hippel-Lindau disease tumor suppressor gene in familial and sporadic cerebellar hemangioblastomas. Am J Clin Pathol. 1997 Apr;107(4):459–466. doi: 10.1093/ajcp/107.4.459. [DOI] [PubMed] [Google Scholar]
  26. Vortmeyer A. O., Gnarra J. R., Emmert-Buck M. R., Katz D., Linehan W. M., Oldfield E. H., Zhuang Z. von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol. 1997 May;28(5):540–543. doi: 10.1016/s0046-8177(97)90075-7. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES